Patient safety: Q&A with Masimo founder Joe Kiani

January 14, 2013 by Arezu Sarvestani

Masimo founder & CEO Joe Kiani tells MassDevice.com how closed healthcare data leads to patient injuries and deaths and the business reasons that the data has stayed closed for so long.

Masimo founder and CEO Joe Kiani

Healthcare companies are running out of reasons to keep their data behind closed doors, according to Masimo (NSDQ:MASI) founder & CEO Joe Kiani.

The technology needed to enable transparency is already here, so it comes down to a matter of leadership, he told attendees during the Patient Safety, Science & Technology Summit spearheaded by Masimo's Foundation for Ethics, Innovation & Competition in Healthcare, which took place in Laguna Beach, Calif., yesterday and today.

"I'm not any less guilty than my colleagues, who are all hoping that we'll take advantage of our own data in a way that will be very profitable," Kiani told MassDevice.com at the close of Sunday's presentations. "I think we're waking up to say, 'You know what, while we haven't thought about how to make money out of that, patients are dying.'"

Sign up to get our free newsletters delivered right to your inbox.

Kiani told us about the spirit of openness, the opportunity for healthcare to catch up with other industries in terms of information innovation, and some of the motivators behind the push for better patient safety – including the death of a 12-year-old boy.

MassDevice: Given the importance of integrated medical device data in the interest of patient safety, why has it taken so long for medtech companies to open up their data and work toward integration?

Comments

Features

ResMed CEO Mick Farrell tells MassDevice.com about the history of ResMed, its sleep apnea devices and the future of treating chronic disease.

Dr. Robert Greenberg, founder & CEO of Second Sight Medical, chats with MassDevice.com in advance of his appearance at the Big 100 West to discuss the Argus II 'bionic eye.'

CEO Josh Kornberg tells MassDevice.com about cleaning house and how bad news for rival Stryker Corp. is helping to reinvigorate Skyline Medical.

In this MassDevice.com podcast, we speak with Glooko CEO Rick Altinger about the company's mobile diabetes management application for smartphones and how it has the potential to change the spectrum of care for one of the world's most common chronic diseases.

Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp